Federal Register / Vol. 72, No.
223 / Tuesday, November 20, 2007 / Notices
GENERAL SERVICES
ADMINISTRATION
[OMB Control No. 3090–0221]
Civilian Board of Contract Appeals;
Information Collection; Civilian Board
of Contract Appeals Rules of
Procedure
AGENCY: Civilian Board of Contract
Appeals, GSA.
ACTION: Notice of request for comments
regarding a revision to an existing OMB
clearance.
SUMMARY: Under the provisions of the
Paperwork Reduction Act of 1995 (44
U.S.C. Chapter 35), the General Services
Administration will be submitting to the
Office of Management and Budget
(OMB) a request to review and approve
an extension of a currently approved
information collection requirement
regarding the Civilian Board of Contract
Appeals (CBCA) Rules of Procedure.
The clearance currently expires on
January 31, 2008.
Public comments are particularly
invited on: Whether this collection of
information is necessary and whether it
will have practical utility; whether our
estimate of the public burden of this
collection of information is accurate and
based on valid assumptions and
methodology; and ways to enhance the
quality, utility, and clarity of the
information to be collected.
DATES: Submit comments on or before:
January 22, 2008.
FOR FURTHER INFORMATION CONTACT:
Margaret S. Pfunder, Chief Counsel,
Civilian Board of Contract Appeals,
1800 F Street, NW., Washington, DC
20405, telephone (202) 606–8800 or via
e-mail to Margaret.Pfunder@gsa.gov.
ADDRESSES: Submit comments regarding
this burden estimate or any other aspect
of this collection of information,
including suggestions for reducing this
burden to the Regulatory Secretariat
(VIR), General Services Administration,
Room 4035, 1800 F Street, NW.,
Washington, DC 20405. Please cite OMB
Control No. 3090–0221, Civilian Board
of Contract Appeals Rules Procedure, in
all correspondence.
SUPPLEMENTARY INFORMATION:
A. Purpose
The CBCA requires the information
collected in order to conduct
proceedings in contract appeals and
petitions, and cost applications. Parties
include those persons or entities filing
pwalker on PROD1PC71 with NOTICES
appeals, petitions, cost applications,
and government agencies.
B. Annual Reporting Burden
Respondents: 55.
VerDate Aug<31>2005 17:01 Nov 19, 2007 Jkt 214001
65341
Responses Per Respondent: 1.
Hours Per Response: .117.
Total Burden Hours: 6.4.
Obtaining Copies of Proposals:
Requesters may obtain a copy of the
information collection documents from
the General Services Administration,
Regulatory Secretariat (VIR), 1800 F
Street, NW., Room 4035, Washington,
DC 20405, telephone (202) 501–4755.
Please cite OMB Control No. 3090–0221,
Civilian Board of Contract Appeals
Rules of Procedure, in all
correspondence.
Dated: October 30, 2007
Casey Coleman,
Chief Information Officer.
[FR Doc. E7–22603 Filed 11–19–07; 8:45 am]
BILLING CODE 6820–AL–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Advisory Committee on
Blood Safety and Availability
AGENCY: Department of Health and
Human Services, Office of the Secretary.
ACTION: Notice.
SUMMARY: As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Services is hereby giving notice that the
Advisory Committee on Blood Safety
and Availability (ACBSA) will hold a
meeting. The meeting will be open to
the public.
DATES: The meeting will take place
Wednesday, January 9, 2008 and
Thursday, January 10, 2008 from 9 a.m.
to 5 p.m.
ADDRESSES: The Westin Washington, DC
City Center, 1400 M Street, NW.,
Washington, DC 20005. Phone: (202)
429–1700.
FOR FURTHER INFORMATION CONTACT: Jerry
A. Holmberg, PhD, Executive Secretary,
Advisory Committee on Blood Safety
and Availability, Office of Public Health
and Science, Department of Health and
Human Services, 1101 Wootton
Parkway, Room 250, Rockville, MD
20852, (240) 453–8803, Fax (240) 453–
8456, e-mail ACBSA@hhs.gov.
SUPPLEMENTARY INFORMATION: Since the
early 1980s there has been a heightened
awareness of transfusion and
transplantation safety. The formation of
the ACBSA directly resulted out of
concern regarding infectious diseases
and the safety of the blood supply. At
this session of the ACBSA, the
Committee will discuss further safety
developments to enhance transfusion
and transplantation safety. These
discussions will include the current
PO 00000 Frm 00054 Fmt 4703 Sfmt 4703
landscape and residual risk of known
and unknown pathogens. In addition,
the Committee will look at needs and
barriers to potential opportunities in
donor screening and technologies for
pathogen reduction.
The public will be given opportunity
to provide comments to the Committee
on January 9 and 10, 2008. Comments
will be limited to five minutes per
speaker. Anyone planning to comment
is encouraged to contact the Executive
Secretary at his/her earliest
convenience. Those who wish to have
printed material distributed to Advisory
Committee members should submit, at a
minimum, one copy of the material, to
the Executive Secretary prior to close of
business January 7, 2008. Likewise,
those who wish to utilize electronic data
projection to the Committee must
submit their materials to the Executive
Secretary prior to close of business
January 7, 2008.
Dated: November 13, 2007.
Jerry A. Holmberg,
Executive Secretary, Advisory Committee on
Blood Safety and Availability.
[FR Doc. E7–22653 Filed 11–19–07; 8:45 am]
BILLING CODE 4150–41–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007N–0220]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Animal Drug User
Fee Cover Sheet, FDA Form 3546
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by December
20, 2007.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
baguilar@omb.eop.gov. All comments
should be identified with the OMB
control number 0910–0539. Also
E:\FR\FM\20NON1.SGM 20NON1
 65342 Federal Register / Vol. 72, No. 223 / Tuesday, November 20, 2007 / Notices
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley Jr. Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
1472.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Animal Drug User Fee Cover Sheet;
FDA Form 3546; 21 U.S.C. 379j–12;
(OMB Control Number: 0910–0539)—
Extension
Under Section 740 of the act, as
amended by ADUFA (21 U.S.C. 379j–
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
21 U.S.C. 379j–12
740(a)(1)
FDA Form 3546 (Cover Sheet)
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: November 14, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–22649 Filed 11–19–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HOMELAND
SECURITY
Bureau of Customs and Border
Protection
FBI Fingerprint Fee
AGENCY: Bureau of Customs and Border
Protection, U.S. Department of
Homeland Security.
ACTION: General notice.
SUMMARY: This document announces
that the fee collected by Customs and
Border Protection regarding the
submission of fingerprints for those
applying for certain positions or
requesting various identification cards
which necessitate a fingerprint records
check, will be raised to a total of $32.49
to offset the fee being charged Customs
and Border Protection by the Federal
pwalker on PROD1PC71 with NOTICES
Bureau of Investigation.
EFFECTIVE DATES: November 20, 2007.
FOR FURTHER INFORMATION CONTACT:
Customs and Border Protection, Office
of International Trade, Broker
VerDate Aug<31>2005 17:01 Nov 19, 2007 Jkt 214001
12), FDA has the authority to assess and
collect for certain animal drug user fees.
Because the submission of user fees
concurrently with applications and
supplements is required, review of an
application cannot begin until the fee is
submitted. The types of fees that require
a cover sheet, are certain animal drug
application fees and certain
supplemental animal drug application
fees. The cover sheet FDA Form 3546,
is designed to provide the minimum
necessary information to determine
whether a fee is required for the review
of an application or supplement, to
determine the amount of the fee
required, and to assure that each animal
drug user fee payment and each animal
drug application for which payment is
made, is appropriately linked to that
payment. The form, when completed
Number of Annual Frequency
Respondents per Response
69 1 time for each
application
Compliance Branch, Tel. (202) 863–
6543.
SUPPLEMENTARY INFORMATION:
Background
The Federal Bureau of Investigation
(FBI) is authorized to charge a fee for
processing fingerprint identification
records for non-law enforcement
employment and licensing purposes.
See Note to 28 U.S.C. 534.
Customs and Border Protection (CBP)
has traditionally used the FBI
fingerprinting services. The Customs
Regulations were amended by T.D. 93–
18 (58 FR 15770, dated March 24, 1993)
to provide that CBP will charge a fee to
recover the FBI fingerprinting costs,
plus an additional 15% of that amount
to cover CBP administrative processing.
The authority for CBP to assess such a
fee is 31 U.S.C. 9701. The port director
advises those required to submit the fee
of the correct amount.
The current user fee charged by the
FBI is $28.25. Accordingly, in this
document, notice is hereby given that
the fee charged by CBP will be raised to
a total of $32.49: $28.25 representing the
FBI portion of the fee, and $4.24
representing the 15% CBP charges to
cover administrative processing.
PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 E:\FR\FM\20NON1.SGM
electronically, will result in the
generation of a unique payment
identification number used for tracking
the payment. FDA will use the
information collected to initiate
administrative screening of new animal
drug applications and supplements to
determine if payment has been received.
In a Federal Register of June 15, 2007
(72 FR 33231), FDA published a 60-day
notice soliciting public comment on the
proposed collection of information
provisions. In response to that notice,
no comments were received.
Respondents to this collection of
information are new animal drug
sponsors applicants or manufacturers.
FDA estimates the burden of this
collection of information as follows:
Total annual Hours per
Total Hours
Responses Response
69 1 69
Dated: November 15, 2007.
Daniel Baldwin,
Assistant Commissioner, Office of
International Trade.
[FR Doc. E7–22646 Filed 11–19–07; 8:45 am]
BILLING CODE 9111–14–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–5117–N–97]
Notice of Submission of Proposed
Information Collection to OMB;
Housing Discrimination Information
Form (HUD–903.1)
AGENCY: Office of the Chief Information
Officer, HUD
ACTION: Notice.
SUMMARY: The proposed information
collection requirement described below
has been submitted to the Office of
Management and Budget (OMB) for
review, as required by the Paperwork
Reduction Act. The Department is
soliciting public comments on the
subject proposal.
This information collection is
necessary to establish HUD’s
jurisdiction to investigate housing
discrimination complaints filed under
the Fair Housing Act. The information
is used to contact the aggrieved person,
and to assess the complaint allegations.
20NON1